Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $20.95, but opened at $20.31. Vera Therapeutics shares last traded at $20.62, with a volume of 155,891 shares trading hands.Get Vera Therapeutics alerts:Analysts Set New Price TargetsAnalysts Can't Get Enough of These Little-Known Biopharma StocksSeveral brokerages recently weighed in on VERA. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday. Cantor Fitzgerald cut their price objective on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Wedbush decreased their target price on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Vera Therapeutics has an average rating of "Moderate Buy" and an average price target of $65.00.Check Out Our Latest Analysis on Vera TherapeuticsVera Therapeutics Stock Down 3.2%The firm's 50 day simple moving average is $22.90 and its 200-day simple moving average is $25.50. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -6.76 and a beta of 1.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 27.68 and a quick ratio of 27.68. Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business earned ($0.56) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year. Insider Buying and Selling at Vera TherapeuticsIn related news, Director Patrick G. Enright acquired 40,607 shares of Vera Therapeutics stock in a transaction on Tuesday, June 24th. The stock was purchased at an average cost of $22.35 per share, with a total value of $907,566.45. Following the purchase, the director directly owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. The trade was a 1.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 16.30% of the company's stock. Hedge Funds Weigh In On Vera TherapeuticsInstitutional investors and hedge funds have recently added to or reduced their stakes in the business. J. Safra Sarasin Holding AG acquired a new position in Vera Therapeutics during the second quarter worth about $697,000. Platinum Investment Management Ltd. raised its stake in shares of Vera Therapeutics by 14.7% during the 2nd quarter. Platinum Investment Management Ltd. now owns 159,751 shares of the company's stock worth $3,764,000 after buying an additional 20,433 shares during the last quarter. GC Wealth Management RIA LLC purchased a new stake in shares of Vera Therapeutics in the 2nd quarter worth about $320,000. Perigon Wealth Management LLC acquired a new stake in Vera Therapeutics in the 2nd quarter valued at about $245,000. Finally, Fifth Third Bancorp purchased a new position in Vera Therapeutics during the 2nd quarter valued at about $102,000. Institutional investors and hedge funds own 99.21% of the company's stock. Vera Therapeutics Company Profile (Get Free Report)Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.Featured ArticlesFive stocks we like better than Vera TherapeuticsGrowth Investing: Should You Adopt This Investing Strategy in 2022?AMD Outperforming NVIDIA: What’s Behind It and Can It Continue?Roth IRA Calculator: Calculate Your Potential ReturnsStrategy Insiders Buy In While Analysts Predict Big UpsideInsider Trades May Not Tell You What You Think3 Surprising Earnings Winners Changing Their Market NarrativeThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Vera Therapeutics Right Now?Before you consider Vera Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here